bioAffinity Technologies, Inc.

BIAF

US09076W1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.37 ^USD	-1.66%		-14.75%	+61.17%

Apr. 01	BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	BioAffinity Technologies, Inc. announced that it has received $2.624 million in funding	CI

BioAffinity Technologies, Inc. announced that it has received $2.624 million in funding

March 19, 2024

On March 20, 2024, bioAffinity Technologies, Inc. closed the transaction. The transaction included participation from three investors.

Latest news about bioAffinity Technologies, Inc.

BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
BioAffinity Technologies, Inc. announced that it has received $2.624 million in funding	Mar. 19	CI
BioAffinity Technologies Closes $2.5 Million Equity Offerings	Mar. 08	MT
BioAffinity Technologies, Inc. announced that it expects to receive $2.624 million in funding	Mar. 05	CI
BioAffinity Technologies, Inc. Appoints Sandeep Bansal to Medical and Scientific Advisory Board	Feb. 06	CI
Transcript : BioAffinity Technologies, Inc. - Special Call	Jan. 09
BioAffinity Technologies, Inc. Appoints Jamie Platt, Ph.D., to its Board of Directors	Dec. 05	CI
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q3 Revenue $298,484	Nov. 14	MT
BioAffinity Technologies, Inc. Provides Earnings Guidance for the Year 2023 and for the Next 12 Months(fourth quarter 2023 to third quarter 2024)	Nov. 14	CI
BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
BioAffinity Technologies, Inc. Appoints Dallas J. Coleman as National Director of Sales	Nov. 06	CI
BioAffinity Technologies Files Registration Statement for Planned Offering of Units at Assumed Price of $1.62 a Unit	23-09-21	MT
BioAffinity Technologies, Inc. Announces Board Changes	23-09-20	CI
Transcript : BioAffinity Technologies, Inc. - Special Call	23-09-19
BioAffinity Technologies Unit Acquires Precision Pathology Services Laboratory Assets; Shares Rise	23-09-19	MT
Transcript : BioAffinity Technologies, Inc. - Special Call	23-09-17
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Reports Q2 Revenue $19,738	23-08-14	MT
BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
AMA Issues CPT Code for bioAffinity Technologiesâ€™ CyPathÂ® Lung Test for Early-Stage Lung Cancer	23-07-12	CI
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q1 Revenue $921	23-05-15	MT
BioAffinity Technologies, Inc. Announces CFO Changes	23-05-02	CI
Transcript : BioAffinity Technologies, Inc., Q4 2022 Earnings Call, Apr 03, 2023	23-04-03
BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
BioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath Lung for Noninvasive Detection of Early-Stage Lung Cancer	23-03-28	CI

Chart bioAffinity Technologies, Inc.

Duration

Period

More charts

bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostic tests using flow cytometry and automated analysis developed by artificial intelligence (AI). Its diagnostic tests analyze cell populations, including cancer and cancer-related cells, that are indicative of a specific diseased state. Its first product, CyPath Lung, is a noninvasive test that addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening. CyPath Lung is marketed as a Laboratory Developed Test.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOAFFINITY TECHNOLOGIES, INC.	+61.17%	27.29M
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances